Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$84.1 - $120.5 $13,119 - $18,798
156 New
156 $14,000
Q2 2022

Aug 12, 2022

SELL
$45.23 - $70.15 $9,362 - $14,521
-207 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$82.78 - $101.0 $6,374 - $7,777
77 Added 59.23%
207 $18,000
Q2 2020

Aug 10, 2020

SELL
$57.09 - $79.27 $3,710 - $5,152
-65 Reduced 33.33%
130 $10,000
Q1 2020

May 14, 2020

SELL
$48.11 - $82.22 $2,453 - $4,193
-51 Reduced 20.73%
195 $11,000
Q4 2019

Feb 12, 2020

BUY
$66.73 - $82.59 $1,668 - $2,064
25 Added 11.31%
246 $19,000
Q1 2019

May 14, 2019

BUY
$48.7 - $86.6 $1,558 - $2,771
32 Added 16.93%
221 $0
Q3 2018

Nov 14, 2018

BUY
$58.91 - $78.32 $1,590 - $2,114
27 Added 16.67%
189 $0
Q3 2017

Nov 08, 2017

BUY
$42.37 - $69.67 $6,863 - $11,286
162
162 $0

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.65B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track R Pg Family Wealth Advisory, LLC Portfolio

Follow R Pg Family Wealth Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of R Pg Family Wealth Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on R Pg Family Wealth Advisory, LLC with notifications on news.